Abstract
The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Current Pharmaceutical Design
Title: Humanized SCID Mice Models of SLE
Volume: 17 Issue: 13
Author(s): Nikola Kerekov, Nikolina Mihaylova, Jozsef Prechl and Andrey Tchorbanov
Affiliation:
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Abstract: The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Export Options
About this article
Cite this article as:
Kerekov Nikola, Mihaylova Nikolina, Prechl Jozsef and Tchorbanov Andrey, Humanized SCID Mice Models of SLE, Current Pharmaceutical Design 2011; 17 (13) . https://dx.doi.org/10.2174/138161211795703780
DOI https://dx.doi.org/10.2174/138161211795703780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges in Current Drug Delivery from the Potential Application of Pharmacogenomics and Personalized Medicine in Clinical Practice
Current Drug Delivery Virtual Screening for the Development of Dual-Inhibitors Targeting Topoisomerase IB and Tyrosyl-DNA Phosphodiesterase 1
Current Drug Targets Drosophila melanogaster As a Model Host for the Study of Microbial Pathogenicity And the Discovery of Novel Antimicrobial Compounds
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease
Current Chemical Biology Genetically Engineered Bacteriocins and their Potential as the Next Generation of Antimicrobials
Current Pharmaceutical Design Total Syntheses and Anti-inflammatory Evaluations of Karanjin and its Natural Analogues
Letters in Organic Chemistry Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Application of Electroporation in DNA Vaccination Protocols
Current Gene Therapy Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology The Use of Naltrexone in Dermatology. Current Evidence and Future Directions
Current Drug Targets Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry The Signaling Pathways in Nitric Oxide Production by Neutrophils Exposed to N-nitrosodimethylamine
Letters in Drug Design & Discovery Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Strategies to Diminish the Ab Load in Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Biological Effects of Licochalcones
Mini-Reviews in Medicinal Chemistry Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences